Ad isf35

Drug Overview

Ad isf35 is an innovative biological treatment designed to “unmask” cancer cells so the body’s own immune system can find and destroy them. It is an Immunotherapy that uses a modified virus to deliver a genetic message directly into a tumor. This message teaches the immune system to recognize cancer as a threat.

• Generic Name: Ad-ISF35 (also known as ISF35 or rAd-CD154)
• US Brand Names: Investigational (No commercial brand name yet)
• Drug Class: Gene Therapy / Immunotherapy / CD40 Agonist
• Route of Administration: Intratumoral (injected directly into the tumor) or Intranodal (injected into a lymph node)
• FDA Approval Status: Investigational. As of 2026, Ad-ISF35 is in clinical trials (Phase I and Phase II). It has not yet been approved for general sale by the FDA, but it has shown promise in trials for blood cancers and melanoma.

What Is It and How Does It Work? (Mechanism of Action)

Ad-ISF35 is a “Smart Immunotherapy” that acts as a biological spark to ignite the immune system. It works through a sophisticated two-step process at the molecular level:

• The Viral Delivery: The “Ad” in the name stands for Adenovirus. Scientists have taken a common cold virus and modified it so it cannot cause a cold. Instead, it acts like a delivery truck to carry a specific gene called CD154 (also known as CD40 ligand) directly into the cancer cells or the cells surrounding them.
• Activating the “Bystander” Effect: Once the gene is inside the tumor, the cells start producing the CD154 protein on their surface. This protein is like a “help signal.”
• The CD40 Switch: The CD154 protein binds to a receptor called CD40 found on immune cells (like B cells and dendritic cells). When this “switch” is flipped, it wakes up the immune system.
• Systemic Response: Not only are the injected tumor cells attacked, but the immune system also learns to recognize the cancer’s “fingerprint.” This creates a “bystander effect,” where the immune system begins attacking other cancer cells throughout the body, even those that were never injected.

FDA Approved Clinical Indications

Currently, Ad-ISF35 is only used in clinical trials. It is being studied for the following conditions:

Oncological Uses (Investigational)

• Chronic Lymphocytic Leukemia (CLL): Helping the body’s immune system recognize and kill leukemia cells.
• Non-Hodgkin’s Lymphoma (NHL): Including Follicular, Mantle Cell, and Diffuse Large B-cell Lymphomas.
• Refractory Metastatic Melanoma: Being studied in combination with other immunotherapies (like pembrolizumab/Keytruda) for skin cancer that hasn’t responded to other treatments.

Non-Oncological Uses

• There are currently no non-oncological uses for Ad-ISF35.

Dosage and Administration Protocols

Because Ad-ISF35 is an investigational drug, the exact dose depends on the specific clinical trial protocol. It is typically given as a direct injection.

Clinical Efficacy and Research Results

Recent data (2020–2026) suggests that Ad-ISF35 is effective at triggering a full-body immune response from a single local injection.

• Leukemia Responses: In Phase I/II trials for CLL, many patients saw a significant reduction in their leukemia cell counts and a shrinking of their lymph nodes and spleen.
• Lymphoma Regression: In animal models and early human trials, direct injection has led to a complete “disappearance” (regression) of the injected tumor in over 80% of cases.
• Combination Therapy: When used with “checkpoint inhibitors” (like Keytruda), researchers are seeing a “1+1=3” effect, where the two drugs work better together than either does alone to stop melanoma from spreading.

Safety Profile and Side Effects

Ad-ISF35 is generally well-tolerated because it is injected locally rather than being sent through the entire bloodstream.

Common Side Effects (>10%)

• Injection Site Pain: Mild pain or redness where the needle entered the tumor.
• Flu-like Symptoms: Chills, fever, and muscle aches. These are actually a “good sign” that the immune system is waking up. They usually disappear within 24 to 48 hours.
• Fatigue: Feeling tired for a few days after treatment.

Serious Adverse Events

• Grade 3/4 Lab Changes: In some high-dose trials, patients had temporary drops in phosphate levels (hypophosphatemia) or white blood cell counts (neutropenia), which returned to normal without treatment.
• Cytokine Release: While rare with this drug, any immunotherapy carries a small risk of the immune system becoming too active, leading to high fevers.

Management Strategies

• For Flu-like Symptoms: Patients can usually take acetaminophen (Tylenol) to manage fevers and aches.
• Monitoring: Patients are often kept in the clinic for a few hours after the injection to ensure they do not have an allergic reaction.

Research Areas

Ad-ISF35 is a prime example of Gene-Based Immunotherapy. Unlike traditional stem cell therapy that replaces cells, Ad-ISF35 “reprograms” the patient’s existing cells. Current research is exploring how to use this drug to turn “cold” tumors (those the immune system ignores) into “hot” tumors (those the immune system attacks). This makes it a major area of study for combining regenerative medicine and other advanced biological therapies.

Patient Management and Practical Recommendations

Pre-Treatment Tests to be Performed

• Imaging (CT or MRI): To locate the best tumors for injection.
• Blood Panels: Standard CBC and metabolic panels to check overall health.
• Tumor Biopsy: To confirm the type of cancer cells present.

Precautions During Treatment

• Since this is a viral-based therapy, patients should discuss any history of severe viral allergies with their doctor.
• Avoid taking high-dose steroids (unless prescribed) during treatment, as steroids can “quiet” the immune system that the drug is trying to “wake up.”

“Do’s and Don’ts” List

• Do expect a mild fever; it’s a sign the medicine is working.
• Do stay hydrated before and after your injection.
• Don’t be alarmed if your lymph nodes feel slightly swollen or tender; this often happens as immune cells move into the area.
• Don’t skip your follow-up blood tests, as these are used to track how your immune system is responding.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Ad-ISF35 is an investigational drug and is not currently approved by the FDA for the treatment of any cancer outside of clinical trials. Always consult with a qualified oncologist or healthcare professional regarding diagnosis, treatment options, and the appropriateness of clinical trials for your specific medical condition.